ArticleLancet (London, England)2020
Interferon beta-1b for COVID-19.
Article in Lancet (London, England), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
47 citing papers in PubMed, 1 synthesis or guideline pooled it, 70 citations in OpenAlex.
- COVID-19 and disease-modifying therapies in patients with demyelinating diseases of the central nervous system: A systematic review.Multiple sclerosis and related disorders · 2021Pooled it
- Randomized controlled open label trial on the use of favipiravir combined with inhaled interferon beta-1b in hospitalized patients with moderate to severe COVID-19 pneumonia.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2021Trial
- Switching of OAS1 splicing isoforms overcomes SNP-derived vulnerability to SARS-CoV-2 infection.BMC biology · 2025Article
- Is there sufficient evidence to support the health benefits of including donkey milk in the diet?Frontiers in nutrition · 2024Review
- Modulation of Human Macrophages by Plasma from COVID-19 Patients Following BCG Vaccination: BATTLE Trial.International journal of general medicine · 2024Article
- Global Perspective on COVID-19 Therapies, Cardiovascular Outcomes, and Implications for Long COVID: A State-of-the-Art Review.Journal of community hospital internal medicine perspectives · 2024Review
- Bovine colostrum and its potential contributions for treatment and prevention of COVID-19.Frontiers in immunology · 2023Review
- Defining the characteristics of interferon-alpha-stimulated human genes: insight from expression data and machine learning.GigaScience · 2022Article
- Lysozyme and Its Application as Antibacterial Agent in Food Industry.Molecules (Basel, Switzerland) · 2022Review
- Interferon resistance of emerging SARS-CoV-2 variants.Proceedings of the National Academy of Sciences of the United States of America · 2022Article
- Development of an efficient reproducible cell-cell transmission assay for rapid quantification of SARS-CoV-2 spike interaction with hACE2.Cell reports methods · 2022Article
- Comparative Toxicity of Interferon Beta-1a Impurities of Heavy Metal Ions.Medicina (Kaunas, Lithuania) · 2022Article
- NSAIDs/nitazoxanide/azithromycin repurposed for COVID-19: potential mitigation of the cytokine storm interleukin-6 amplifier via immunomodulatory effects.Expert review of anti-infective therapy · 2022Article
- Immune dysregulation and immunopathology induced by SARS-CoV-2 and related coronaviruses - are we our own worst enemy?Nature reviews. Immunology · 2022Review
- Interferon Resistance of Emerging SARS-CoV-2 Variants.bioRxiv : the preprint server for biology · 2021Article
- Sex differences in innate anti-viral immune responses to respiratory viruses and in their clinical outcomes in a birth cohort study.Scientific reports · 2021Article
- Effectiveness of Natural Antioxidants against SARS-CoV-2? Insights from theAntibiotics (Basel, Switzerland) · 2021Article
- Update on the management of multiple sclerosis during the COVID-19 pandemic and post pandemic: An international consensus statement.Journal of neuroimmunology · 2021Review
- COVID-19 as a mediator of interferon deficiency and hyperinflammation: Rationale for the use of JAK1/2 inhibitors in combination with interferon.Cytokine & growth factor reviews · 2021Review
- Microwave Modification as an Excellent Way to Produce Unique Lysozyme with Potential for Food and Human Health.Foods (Basel, Switzerland) · 2021Article
Corrections and comments
- Comment on
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.